CRL · Charles River Laboratories International, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Charles River returned to organic revenue growth (0.1%) and beat prior EPS outlook, raising full-year organic revenue guidance by 150 bps and non-GAAP EPS by $0.25 at midpoint, driven by a sharp pickup in DSA bookings (net book-to-bill of 1.19x, highest in nearly four years).
- + Returned to total organic revenue growth of 0.1% in Q2, the first since Q3 2023.
- + Q2 results exceeded prior outlook on both revenue and non-GAAP EPS.
- + Raised full-year 2026 organic revenue guidance by 150 bps and non-GAAP EPS guidance by $0.25 at midpoint.
- + Raised DSA segment outlook to low single-digit organic revenue growth for 2026.
- + Expects at least 500 bps of non-GAAP operating margin expansion in the second half of 2026.
- + Raised full-year free cash flow guidance to $400–$420M from $375–$400M.
- − Q2 GAAP net loss of $(0.03) per share versus $1.06 in the prior-year quarter, driven by a $63.7M ($1.40/share) CDMO/Cell Solutions divestiture loss.
- − Non-GAAP EPS guidance reduced by a higher tax rate (~23–24%, up ~100 bps), an approximate $0.20 per share headwind.
- − RMS organic revenue declined 1.4% in Q2 on lower North American small models and research model services volume.
- − Unallocated corporate costs rose to 7.2% of revenue in Q2 (from 5.9%), and full-year corporate cost outlook raised to ~6.0% from ~5.5%.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRL
this stock
Charles River Laboratories International, Inc.
|
$14.20B | +47.9% | +10.5% | — | 4.7% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +16.5% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$155.42B | -3.2% | +8.5% | 39.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +80.4% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +26.6% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRL | +6.4% | +4.5% | +68.1% | +2.4% | +47.9% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +7.1% | +4.4% | +55.9% | +2.9% | +36.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.